🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for MDS/MPN

Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN NCT05817955Phase 21 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Azacitidine (AZA) with Ruxolitinib Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) NCT04061421Phase 1, Phase 24 sites📍 Tampa📍 Rochester📍 Portland Michael Savona · Tests: ASTX727, Itacitinib, Ruxolitinib A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations NCT07143669n/a26 sites📍 Birmingham📍 Birmingham📍 Scottsdale Blueprint Medicines Corporation · Tests: Screening A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation NCT06859424Phase 213 sites📍 Birmingham📍 Duarte📍 Palo Alto Center for International Blood and Marrow Transplant Resear… · Tests: Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction NCT06211166n/a1 site📍 Beijing Peking University People's Hospital · Tests: Digital PCR, Quantitative PCR, MFC Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation NCT06892223Phase 22 sites📍 Genova📍 Rozzano Istituto Clinico Humanitas · Tests: Monalizumab (anti-NKG2A monoclonal antibody) MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) NCT07362225n/a2 sites📍 Chicago📍 New York MPN Research Foundation 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies NCT04187703EARLY Phase 11 site📍 Cleveland Benjamin Tomlinson · Tests: 5-azacytidine, Decitabine A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials NCT04064060Phase 3143 sites📍 Los Angeles📍 Oakland📍 Stanford Celgene · Tests: Luspatercept (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis NCT04996875Phase 242 sites📍 Birmingham📍 Phoenix📍 Duarte Cogent Biosciences, Inc. · Tests: bezuclastinib Caris Chromoseq Data Collection NCT07680868n/a1 site📍 Phoenix Caris Science, Inc. · Tests: Caris Chromoseq Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis NCT07612280Phase 1, Phase 27 sites📍 Sydney📍 Sydney📍 Adelaide Jubilant Therapeutics Inc. · Tests: JBI-802 Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN NCT07710534Phase 21 site📍 Richmond Virginia Commonwealth University · Tests: Decitabine-cedazuridine plus venetoclax (DEC-C+VEN), Azacitidine plus venetoclax (AZA+VEN) Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies NCT07565220Phase 11 site📍 Pittsburgh Sawa Ito, MD · Tests: Thiotepa, Fludarabine, Busulfan, PBSC infusion Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms NCT05549661Phase 11 site📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib, Ultrasound Imaging A Study of BGB-11417 in Participants With Myeloid Malignancies NCT04771130Phase 1, Phase 247 sites📍 Duarte📍 Tampa📍 Pittsburgh BeOne Medicines · Tests: BGB-11417, Azacitidine, Posaconazole, BGB-11417, BGB-11417 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. NCT04771572Phase 18 sites📍 Chicago📍 Boston📍 Chapel Hill Newave Pharmaceutical Inc · Tests: LP-118 Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia NCT06523556Phase 1, Phase 21 site📍 Columbus Uma Borate · Tests: Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy